EUVIMEDEUVIMED entdecken
Kohortenstudie

Lifetime Risk of Liver Disease in Patients With β‐Thalassemia: Data From the de‐LIGHT Retrospective Cohort Study

Khaled M Musallam iD, Angela Vitrano iD, Alessandro Inzerillo, Rosario Di Maggio iD, Rita Barone, Antonino Giangreco, Maria Concetta Renda iD, Emanuela Fecarotta, Antonio Troia, Antonino Giambona iD, Giovan Battista Ruffo, Efthymia Vlachaki iD und 8 weitere

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14446 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Khaled M Musallam und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Medical City, Abu Dhabi, UAE. Hauptthemen laut MEDLINE: beta-Thalassemia, Liver Diseases. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Agios Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Liver disease is common in patients with β‐thalassemia, but data on lifetime incidence and risk factors are limited.

Methods

We conducted a retrospective cohort study of 557 patients with β‐thalassemia followed from diagnosis for a median of 38 years. Predictive, survival, and regression analyses were used to determine the association between liver disease and potential risk factors.

Results

The crude incidence of liver disease was 26.4% (fibrosis/cirrhosis 24.2%, median age 34.4 years; hepatocellular carcinoma 2.3%, median age 45.4 years, 38.5% not preceded by cirrhosis). Among evaluated risk factors, only hepatitis C virus (HCV) infection (adjusted hazard ratio [HR]: 2.195, p < 0.001) and lifetime serum ferritin level (adjusted HR per 100‐ng/mL increase: 1.030, p < 0.001) were significantly associated with liver disease, with a lifetime serum ferritin level > 1500 ng/mL being the best predictor ( p = 0.001). Liver disease‐free survival was significantly shorter in patients who had both versus either or neither risk factor ( p < 0.001). Mostly severe and persistent but not mild–moderate or temporary/fluctuating elevation in liver enzymes was associated with liver disease development.

Conclusion

Patients with β‐thalassemia have a considerably increased lifetime risk of liver disease that is primarily driven by HCV infection and/or uncontrolled iron overload, especially in the 4th–5th decades of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-ThalassemiaLiver DiseasesHumansMaleFemaleRetrospective StudiesAdultRisk FactorsMiddle AgedIncidenceYoung AdultAdolescentFerritinsHepatitis C

Stichwörter der Autor:innen

cirrhosisfibrosishepatitishepatocellular carcinomairon overload

Substanzen

Ferritins

Autor:innen und Institutionen

  • Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Medical City, Abu Dhabi, UAE.
  • Department of Public Health and Epidemiology, Khalifa University, Abu Dhabi, UAE.
  • Division of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA.
  • Campus of Haematology Franco and Piera Cutino, UOC Ematologia per le Malattie Rare Del Sangue e Degli Organi Ematopoietici, AOOR Villa Sofia-V. Cervello, Palermo, Italy.
  • Laboratorio Biobanca, UOC Ematologia per le Malattie Rare Del Sangue e Degli Organi Ematopoietici, Palermo, Italy.
  • UOSD Diagnostica Molecolare Malattie Rare Ematologiche, AOOR Villa Sofia-Cervello, Palermo, Italy.

ORCID-Profile: Khaled M Musallam, Angela Vitrano, Rosario Di Maggio, Maria Concetta Renda, Antonino Giambona, Efthymia Vlachaki, Paolo Ricchi, Filomena Longo, Aurelio Maggio

Förderung

  • Agios Pharmaceuticals

Zitieren

APA

Musallam, K. M., Vitrano, A., Inzerillo, A., Di Maggio, R., Barone, R., Giangreco, A., Renda, M. C., Fecarotta, E., Troia, A., Giambona, A., Ruffo, G. B., Vlachaki, E., Venou, T. M., Ricchi, P., Ziello, B., Serra, M., Colizzi, E., Longo, F., Culcasi, M., & Maggio, A. (2025). Lifetime Risk of Liver Disease in Patients With β‐Thalassemia: Data From the de‐LIGHT Retrospective Cohort Study. European Journal of Haematology. https://doi.org/10.1111/ejh.14446

Vancouver

Musallam KM, Vitrano A, Inzerillo A, Di Maggio R, Barone R, Giangreco A, et al. Lifetime Risk of Liver Disease in Patients With β‐Thalassemia: Data From the de‐LIGHT Retrospective Cohort Study. European Journal of Haematology. 2025. doi:10.1111/ejh.14446

BibTeX
@article{Musallam2025,
  author = {Musallam, Khaled M and Vitrano, Angela and Inzerillo, Alessandro and Di Maggio, Rosario and Barone, Rita and Giangreco, Antonino and Renda, Maria Concetta and Fecarotta, Emanuela and Troia, Antonio and Giambona, Antonino and Ruffo, Giovan Battista and Vlachaki, Efthymia and Venou, Theodora M and Ricchi, Paolo and Ziello, Brunella and Serra, Marilena and Colizzi, Elena and Longo, Filomena and Culcasi, Martina and Maggio, Aurelio},
  title = {Lifetime Risk of Liver Disease in Patients With β‐Thalassemia: Data From the de‐LIGHT Retrospective Cohort Study},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14446}
}
Kostenlos starten →